PROCEPT BioRobotics (NASDAQ:PRCT) Shares Down 4.8% – Time to Sell?

PROCEPT BioRobotics Corporation (NASDAQ:PRCT)’s share price dropped 4.8% during mid-day trading on Thursday . The company traded as low as $21.17 and last traded at $20.9120. Approximately 125,719 shares were traded during mid-day trading, a decline of 92% from the average session volume of 1,546,816 shares. The stock had previously closed at $21.97.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Negative Sentiment: The lawsuits allege that PROCEPT and certain senior executives failed to disclose inventory problems, weaker-than-expected handpiece sales and repeated late-quarter bulk discounts. Attorneys claim the discount program may have pulled demand forward, inflated recurring-revenue metrics and left customers with excess inventory. Hagens Berman securities fraud class action notice
• Negative Sentiment: Several firms are highlighting a lead-plaintiff deadline of September 22, 2026 for investors who purchased PRCT shares between February 28, 2024, and February 25, 2026. The notices reference an alleged decline of roughly 18% on inventory revelations and, in some claims, a more than 75% decline over the relevant period. The allegations have not been proven in court. SBS class action notice
• Neutral Sentiment: The numerous releases from SBS, Pomerantz, Rosen, Kaplan Fox, ClaimsFiler, Kahn Swick & Foti and other firms largely repeat the same lawsuit and deadline information rather than announce a new operating development. However, the volume of alerts keeps legal and disclosure concerns prominent for investors. Pomerantz investor alert

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on PRCT shares. TD Cowen dropped their target price on PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, August 5th. Robert W. Baird set a $20.00 price target on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Jefferies Financial Group reissued a “hold” rating and issued a $20.00 target price on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. Evercore set a $23.00 target price on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. Finally, Leerink Partners lowered PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $31.00 to $29.00 in a research report on Thursday, June 11th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $25.09.

PROCEPT BioRobotics Stock Down 3.6%

The stock has a market capitalization of $1.21 billion, a P/E ratio of -10.92 and a beta of 0.91. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.35 and a current ratio of 6.55. The firm’s 50-day simple moving average is $20.35 and its 200 day simple moving average is $23.74.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The company had revenue of $94.50 million for the quarter, compared to analyst estimates of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The business’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same period last year, the company posted ($0.35) earnings per share. As a group, research analysts expect that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current year.

Insider Activity

In other news, CEO Larry L. Wood bought 23,900 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the purchase, the chief executive officer owned 23,900 shares of the company’s stock, valued at approximately $498,315. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 1,000 shares of company stock valued at $28,480. 4.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On PROCEPT BioRobotics

Several hedge funds have recently added to or reduced their stakes in PRCT. Caitong International Asset Management Co. Ltd lifted its stake in shares of PROCEPT BioRobotics by 436.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after buying an additional 746 shares during the last quarter. Versant Capital Management Inc increased its stake in PROCEPT BioRobotics by 994.5% during the 2nd quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock worth $27,000 after acquiring an additional 1,084 shares during the period. Nykredit A S acquired a new position in PROCEPT BioRobotics in the second quarter valued at about $27,000. Center for Financial Planning Inc. acquired a new position in PROCEPT BioRobotics in the fourth quarter valued at about $40,000. Finally, US Bancorp DE increased its stake in PROCEPT BioRobotics by 175.7% in the third quarter. US Bancorp DE now owns 1,693 shares of the company’s stock valued at $60,000 after acquiring an additional 1,079 shares during the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.